Scarica l'app Stockscreener
12.86
10.43%
1.215
Agomab Therapeutics Nv Adr Borsa (AGMB) Ultime notizie
Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView
EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView
Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView
EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView
Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView
Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Non-controlling/minority interest of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Earnings and Revenue – TRADEGATE:M5E - TradingView
Free float of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Agomab closes $200 million IPO on NASDAQ - Investing.com India
Agomab closes $200 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
Agomab Announces Closing of Initial Public Offering - Benzinga
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Mint
Agomab Therapeutics opens below IPO price in Nasdaq debut By Investing.com - Investing.com Canada
Agomab prices IPO at $16 per share, aims to raise $200 million - Investing.com Australia
Agomab prices IPO at $16 per share, aims to raise $200 million By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):